11 April 2019

Renal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age.

Because renal and hepatic function are among the main determinants of drug exposure, the pharmacokinetic profile might be altered for patients with cancer who have renal or hepatic impairment, necessitating dose adjustments. Most anticancer drugs are dosed near their maximum tolerated dose and are characterised by a narrow therapeutic index. Consequently, selecting an adequate dose for patients who have either hepatic or renal impairment, or both, is challenging and definitive recommendations on dose adjustments are scarce.

In the Lancet Oncology, Raboudumc researchers from the department of Pharmacy (Stefanie Krens, Nielka van Erp, David Burger) and the department of Medical oncology (Gerben Lassche, Ingrid Desar, Carla van Herpen) wrote a comprehensive review in which they discuss the effect of renal and hepatic impairment on the pharmacokinetics of anticancer drugs. To guide clinicians in selecting appropriate dose adjustments, information from available drug labels and from the published literature were combined to provide a practical set of recommendations for dose adjustments of 160 anticancer drugs for patients with hepatic and renal impairment.

See publication in Lancet Oncology
 

Related news items


The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger

2 November 2021

On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC.

read more

Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis

25 January 2021

Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.

read more

650,000 Euro funding for research into the phasing out of medication for leukaemia patients

30 July 2020

With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.

read more

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)

12 May 2020

In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.

read more

The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV

17 March 2020

In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.

read more

Three Royal decorations for RIHS researchers

29 April 2019

Peter de Smet, Harry Surayapranata and Stans Verhagen received royal honours for their exceptional academic and social achievements.

read more